Subrata Panda &Amp; Sohini Das

Stories by Subrata Panda &Amp; Sohini Das

From Tesla to Mercedes, luxury carmakers head South

From Tesla to Mercedes, luxury carmakers head South

Rediff.com   11 Mar 2025

In 2024 alone, South India saw the highest rise in sales in the luxury segment, with Tamil Nadu reportedly registering a 19.3 per cent increase in premium car registrations from 2022-23

RBI's Sanjay Malhotra is a Governor with a difference!

RBI's Sanjay Malhotra is a Governor with a difference!

Rediff.com   10 Mar 2025

Since Sanjay Malhotra took office as governor in December, the Reserve Bank of India (RBI) has adopted a more accommodative stance, which bodes well for banking and the economy as they navigate a growth slowdown, according to analysts.

This will Likely Shape the Future of Pharma Inc

This will Likely Shape the Future of Pharma Inc

Rediff.com   8 Mar 2025

Indian pharmaceutical companies may have units abroad as part of "distributed manufacturing" across various locations, according to industry veterans. This may come about over the next five to 10 years.

'US tariff issue is an overhanging sword'

'US tariff issue is an overhanging sword'

Rediff.com   7 Mar 2025

Firodia talked about his plans for the EV-components business, and the components business at large for the group

Mankind Pharma Targets Anti-Obesity Drug

Mankind Pharma Targets Anti-Obesity Drug

Rediff.com   6 Mar 2025

'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'

Can Tesla Make In India For Below $23,000?

Can Tesla Make In India For Below $23,000?

Rediff.com   5 Mar 2025

The Indian automotive market offers around 1 million units annual volume opportunity at a price above $23,000.

India Inc holds breath for Trump's new tariffs to kick in

India Inc holds breath for Trump's new tariffs to kick in

Rediff.com   27 Feb 2025

Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.

Why Tesla Entry is No Major Threat

Why Tesla Entry is No Major Threat

Rediff.com   24 Feb 2025

Tesla needs to either sell the same models with reduced features to lower the cost for Indian market, or incur losses.

Kotak Mahindra Bank's margins to improve after ban removal: Brokerages

Kotak Mahindra Bank's margins to improve after ban removal: Brokerages

Rediff.com   21 Feb 2025

Kotak Mahindra Bank's net interest margin is likely to swell after the Reserve Bank of India (RBI) lifted its restrictions on the private lender that barred it from issuing fresh credit cards and onboarding new customers through digital mode, brokerages said on Thursday. The bank's net interest margin (NIM) has seen a decline of over 35 basis points (bps) since the restrictions were imposed by the regulator in April 2024.

Should depositors put money in co-operative banks?

Should depositors put money in co-operative banks?

Rediff.com   18 Feb 2025

The co-operative banking sector is well regulated, and a few cases of restrictions being imposed by the Reserve Bank of India (RBI) should not paint a negative picture of the entire sector, said Department of Economic Affairs (DEA) secretary Ajay Seth on Monday. "Co-operative banks in the country are generally quite robust, and the RBI takes regulatory action whenever issues arise.

Bank Deposits: Govt Plans To Increase Insurance

Bank Deposits: Govt Plans To Increase Insurance

Rediff.com   18 Feb 2025

Currently, deposits of up to Rs 5 lakh are covered under the deposit-insurance scheme.

'Goal for Axis Max Life Insurance is to become listed entity'

'Goal for Axis Max Life Insurance is to become listed entity'

Rediff.com   17 Feb 2025

'However, this process will take some time. Depending on the approval timeline, it may span a few quarters.'

USAID Funding To India Declines Amid Trump's Freeze

USAID Funding To India Declines Amid Trump's Freeze

Rediff.com   13 Feb 2025

'If the Bill and Melinda Gates Foundation cuts funds, there could be more impact.'

Highest Selling New Drug In India Is...

Highest Selling New Drug In India Is...

Rediff.com   11 Feb 2025

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.

'Tariffs will hurt insurance, patients and everyone'

'Tariffs will hurt insurance, patients and everyone'

Rediff.com   10 Feb 2025

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.

Budget Prepares For Rise In Cancer Cases

Budget Prepares For Rise In Cancer Cases

Rediff.com   3 Feb 2025

Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?

Trump's Tariff War: India Waits, Watches

Trump's Tariff War: India Waits, Watches

Rediff.com   3 Feb 2025

'We have to be prepared for the larger disruption that is likely to take place.'

'Should end fourth quarter on a robust note'

'Should end fourth quarter on a robust note'

Rediff.com   2 Feb 2025

'We have opened 100 branches in the last one and a half years. Our manpower is also in place.'

GBS Disease: 16 Patients On Ventilator

GBS Disease: 16 Patients On Ventilator

Rediff.com   27 Jan 2025

Water samples from different parts of Pune have been sent to the public health laboratory for chemical and biological analysis.

Why India Inc is opting for long-term borrowing

Why India Inc is opting for long-term borrowing

Rediff.com   16 Jan 2025

With short-term rates firming up due to tight liquidity conditions, Indian corporates are opting to borrow long term to take advantage of the attractive rates by locking them in these uncertain times. The banking system has a liquidity deficit of over Rs 2 trillion. According to market participants, engineering conglomerate Larsen & Toubro (L&T) raised Rs 1,500 crore through 10-year bonds in December 2024.